1
|
Sakai K, Fuke H, Yoshimura K, Sasaki M, Abe K, Haino S, Hams T, Hasegawa M, Kim KC, Lee MH, Makida Y, Mitchell JW, Nishimura J, Nozaki M, Orito R, Ormes JF, Seo ES, Streitmatter RE, Thakur N, Yamamoto A, Yoshida T. Search for Antideuterons of Cosmic Origin Using the BESS-Polar II Magnetic-Rigidity Spectrometer. Phys Rev Lett 2024; 132:131001. [PMID: 38613296 DOI: 10.1103/physrevlett.132.131001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 10/21/2023] [Accepted: 01/10/2024] [Indexed: 04/14/2024]
Abstract
We searched for antideuterons (d[over ¯]'s) in the 4.7×10^{9} cosmic-ray events observed during the BESS-Polar II flight at solar minimum in 2007-2008 but found no candidates. The resulting 95% C.L. upper limit on the d[over ¯] flux is 6.7×10^{-5} (m^{2} s sr GeV/n)^{-1} in an energy range from 0.163 to 1.100 GeV/n. The result has improved by more than a factor of 14 from the upper limit of BESS97, which had a potential comparable to that of BESS-Polar II in the search for cosmic-origin d[over ¯]'s and was conducted during the former solar minimum. The upper limit of d[over ¯] flux from BESS-Polar II is the first result achieving the sensitivity to constrain the latest theoretical predictions.
Collapse
Affiliation(s)
- K Sakai
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
- Center for Research and Exploration in Space Science and Technology (CRESST)
| | - H Fuke
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara, Kanagawa 252-5210, Japan
| | - K Yoshimura
- Okayama University, Okayama, Okayama 700-8530, Japan
| | - M Sasaki
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
- Center for Research and Exploration in Space Science and Technology (CRESST)
| | - K Abe
- Kobe University, Kobe, Hyogo 657-8501, Japan
| | - S Haino
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Hams
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
- Center for Research and Exploration in Space Science and Technology (CRESST)
| | - M Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K C Kim
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - M H Lee
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - Y Makida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - J W Mitchell
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
| | - J Nishimura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara, Kanagawa 252-5210, Japan
- The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan
| | - M Nozaki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - R Orito
- Kobe University, Kobe, Hyogo 657-8501, Japan
| | - J F Ormes
- University of Denver, Denver, Colorado 80208, USA
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - R E Streitmatter
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
| | - N Thakur
- NASA-Goddard Space Flight Center (NASA-GSFC), Greenbelt, Maryland 20771, USA
| | - A Yamamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - T Yoshida
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (ISAS/JAXA), Sagamihara, Kanagawa 252-5210, Japan
| |
Collapse
|
2
|
Hattori Y, Uda H, Niu A, Yoshimura K, Sugawara Y. Ambulatory sagittal split ramus osteotomy: strategy for enhanced recovery after surgery. Int J Oral Maxillofac Surg 2023; 52:476-480. [PMID: 36100528 DOI: 10.1016/j.ijom.2022.08.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 08/02/2022] [Accepted: 08/16/2022] [Indexed: 11/19/2022]
Abstract
The sagittal split ramus osteotomy (SSRO) has been performed mainly on an inpatient basis because of the duration of anaesthesia and the potential risk of postoperative complications, such as bleeding, pain, nausea, and vomiting. However, advances in both surgical and anaesthetic management have enabled the reduction of these risks and shortened the length of hospital stay. Thus, the SSRO may be feasible even in the ambulatory setting in elective cases. The clinical records of all patients who underwent an outpatient SSRO between August 2011 and September 2020 at Lilla Craniofacial Clinic were reviewed retrospectively. Data on age, sex, duration of surgery, operative procedures, intraoperative bleeding, and admission status were investigated. In total, 143 patients underwent a bilateral SSRO. The SSRO was performed as an isolated procedure in 73 patients and concomitantly with other surgical procedures in the remaining 70 patients. Overall, 142 of the 143 patients were discharged on the day of surgery (99.3%); only one (0.7%) required an overnight stay because of a submental haemorrhage after genioplasty. No emergency hospitalizations or readmissions occurred after discharge. Multimodal perioperative management, both surgical and anaesthetic, facilitated enhanced patient recovery after surgery, and SSRO was performed successfully and safely as an ambulatory procedure.
Collapse
Affiliation(s)
- Y Hattori
- Department of Plastic Surgery, Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku, Tokyo, Japan
| | - H Uda
- Department of Plastic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan; Lilla Craniofacial Clinic Tokyo, Chuo-ku, Tokyo, Japan.
| | - A Niu
- Department of Plastic Surgery, Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku, Tokyo, Japan
| | - K Yoshimura
- Department of Plastic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan
| | - Y Sugawara
- Department of Plastic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan; Lilla Craniofacial Clinic Tokyo, Chuo-ku, Tokyo, Japan
| |
Collapse
|
3
|
Nocerino E, Witteveen C, Kobayashi S, Forslund OK, Matsubara N, Zubayer A, Mazza F, Kawaguchi S, Hoshikawa A, Umegaki I, Sugiyama J, Yoshimura K, Sassa Y, von Rohr FO, Månsson M. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe 2 investigated by [Formula: see text]SR, neutron and X-ray diffraction. Sci Rep 2022; 12:21657. [PMID: 36522382 PMCID: PMC9755140 DOI: 10.1038/s41598-022-25921-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 12/07/2022] [Indexed: 12/23/2022] Open
Abstract
Two-dimensional (2D) triangular lattice antiferromagnets (2D-TLA) often manifest intriguing physical and technological properties, due to the strong interplay between lattice geometry and electronic properties. The recently synthesized 2-dimensional transition metal dichalcogenide LiCrTe[Formula: see text], being a 2D-TLA, enriched the range of materials which can present such properties. In this work, muon spin rotation ([Formula: see text]SR) and neutron powder diffraction (NPD) have been utilized to reveal the true magnetic nature and ground state of LiCrTe[Formula: see text]. From high-resolution NPD the magnetic spin order at base-temperature is not, as previously suggested, helical, but rather collinear antiferromagnetic (AFM) with ferromagnetic (FM) spin coupling within the ab-plane and AFM coupling along the c-axis. The value if the ordered magnetic Cr moment is established as [Formula: see text]. From detailed [Formula: see text]SR measurements we observe an AFM ordering temperature [Formula: see text] K. This value is remarkably higher than the one previously reported by magnetic bulk measurements. From [Formula: see text]SR we are able to extract the magnetic order parameter, whose critical exponent allows us to categorize LiCrTe[Formula: see text] in the 3D Heisenberg AFM universality class. Finally, by combining our magnetic studies with high-resolution synchrotron X-ray diffraction (XRD), we find a clear coupling between the nuclear and magnetic spin lattices. This suggests the possibility for a strong magnon-phonon coupling, similar to what has been previously observed in the closely related compound LiCrO[Formula: see text].
Collapse
Affiliation(s)
- E. Nocerino
- KTH Royal Institute of Technology, Department of Applied Physics, Alba Nova University Center, 114 21 Stockholm, Sweden
| | - C. Witteveen
- Department of Quantum Matter Physics, University of Geneva, 24 Quai Ernest-Ansermet, 1211 Geneva 4, Switzerland
- Department of Physics, University of Zürich, Winterthurerstr. 190, 8057 Zurich, Switzerland
| | - S. Kobayashi
- Japan Synchrotron Radiation Research Institute (JASRI), 1-1-1 Kouto, Sayo, 679-5198 Japan
| | - O. K. Forslund
- Department of Physics, Chalmers University of Technology, 412 96 Göteborg, Sweden
| | - N. Matsubara
- KTH Royal Institute of Technology, Department of Applied Physics, Alba Nova University Center, 114 21 Stockholm, Sweden
| | - A. Zubayer
- Department of Physics, Chemistry and Biology (IFM), Linköping University, 581 83 Linköping, Sweden
| | - F. Mazza
- Insitute of Solid State Physics, TU Wien, Wiedner Haupstraße 8-10, 1040 Vienna, Austria
| | - S. Kawaguchi
- Japan Synchrotron Radiation Research Institute (JASRI), 1-1-1 Kouto, Sayo, 679-5198 Japan
| | - A. Hoshikawa
- Frontier Research Center for Applied Atomic Sciences, Ibaraki University, 162-1 Shirakata, Tokai, Ibaraki 319-1106 Japan
| | - I. Umegaki
- Muon Science Laboratory, Institute of Materials Structure Science, KEK, Tokai, Ibaraki 319-1106 Japan
| | - J. Sugiyama
- Neutron Science and Technology Center, Comprehensive Research Organization for Science and Society (CROSS), Tokai, Ibaraki 319-1106 Japan
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195 Japan
| | - K. Yoshimura
- Department of Chemistry, Graduate School of Science, Kyoto University, Kyoto, 606-8502 Japan
| | - Y. Sassa
- Department of Physics, Chalmers University of Technology, 412 96 Göteborg, Sweden
| | - F. O. von Rohr
- Department of Quantum Matter Physics, University of Geneva, 24 Quai Ernest-Ansermet, 1211 Geneva 4, Switzerland
| | - M. Månsson
- KTH Royal Institute of Technology, Department of Applied Physics, Alba Nova University Center, 114 21 Stockholm, Sweden
| |
Collapse
|
4
|
Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. 990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Mamesaya N, Harada H, Hata A, Konno M, Nakamatsu K, Hayashi H, Yamamoto T, Saito R, Mayahara H, Kokubo M, Sato Y, Yoshimura K, Nishimura Y, Yamamoto N, Nakagawa K. 958P Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab for locally advanced non-small cell lung cancer (NSCLC): A multicenter prospective observational study (WJOG12019L). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Hara H, Masuishi T, Ando T, Kawakami T, Yamamoto Y, Sugimoto N, Shiraishi K, Esaki T, Negoro Y, Tsuzuki T, Sawai H, Nakamura M, Inagaki T, Shinohara Y, Kawakami H, Kawakami K, Katsuya H, Maeda O, Fujita Y, Yoshimura K, Nakajima T, Muro K. P-99 A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Ando T, Nakashima K, Yoshita H, Sakumura M, Nomura M, Muto M, Fujii H, Horie Y, Takeda H, Yoshii T, Tahara Y, Katada C, Yoshimura K, Ishikawa H, Hosokawa A. P-108 A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
8
|
Taniguchi H, Inoue T, Kawa G, Murota T, Tsukino H, Yoshimura K, Kamoto T, Ogawa O, Matsuda T, Kinoshita H. Evaluation of sexual function after dutasteride treatment in patients with once negative prostate biopsy and benign prostate hyperplasia. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.03.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Honma O, Watanabe C, Fukuchimoto H, Kashiwazaki J, Tateba M, Wagatsuma S, Ogata K, Maki K, Sonou H, Shiga K, Otsuka E, Hiruta M, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Toyoda H, Tsurui T, Kuramasu A, Kin M, Kubota Y, Sambe T, Horiike A, Ishida H, Shimada K, Umeda M, Tsunoda T, Yoshimura K. Verification of the Usefulness of an Assessment and Risk Control Sheet that Promotes Management of Cancer Drug Therapy. Front Pharmacol 2022; 13:744916. [PMID: 35222016 PMCID: PMC8864067 DOI: 10.3389/fphar.2022.744916] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Accepted: 01/20/2022] [Indexed: 12/22/2022] Open
Abstract
Background: Proper management of adverse events is crucial for the safe and effective implementation of anticancer drug treatment. Showa University Hospital uses our interview sheet (assessment and risk control [ARC] sheet) for the accurate evaluation of adverse events. On the day of anticancer drug treatment, a nurse conducts a face-to-face interview. As a feature of the ARC sheet, by separately describing the symptoms the day before treatment and the day of treatment and sharing the information on the medical record, it is possible to clearly determine the status of adverse events. In this study, we hypothesized that the usefulness and points for improvement of the ARC sheet would be clarified by using and evaluating a patient questionnaire. Methods: This study included 174 patients (144 at Showa University Hospital (Hatanodai Hospital) and 30 at Showa University Koto Toyosu Hospital (Toyosu Hospital) who underwent pre-examination interviews by nurses and received cancer chemotherapy at the outpatient center of Hatanodai and Toyosu Hospital. In the questionnaire survey, the ARC sheet’s content and quality, respondents’ satisfaction, structural strengths, and points for improvement were evaluated on a five-point scale. Results: The patient questionnaire received responses from 160 participants, including the ARC sheet use group (132 people) and the non-use group (28 people). Unlike the ARC sheet non-use group, the ARC sheet use group recognized that the sheet was useful to understand the adverse events of aphthous ulcers (p = 0.017) and dysgeusia (p = 0.006). In the satisfaction survey questionnaire, there was a high sense of security in the pre-examination interviews by nurses using the ARC sheet. Conclusions: The ARC sheet is considered an effective tool for comprehensively evaluating adverse events. Pre-examination interviews by nurses using ARC sheets accurately determined the adverse events experienced by patients with anxiety and tension due to confrontation with physicians.
Collapse
Affiliation(s)
- O Honma
- Department of Nursing, Showa University Hospital, Tokyo, Japan.,Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan
| | - C Watanabe
- Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan
| | - H Fukuchimoto
- Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan.,Department of Nursing, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - J Kashiwazaki
- Faculty of Nursing, Kyoritsu Women's University, Tokyo, Japan
| | - M Tateba
- Department of Nursing, Showa University Hospital, Tokyo, Japan.,Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan
| | - S Wagatsuma
- Department of Nursing, Showa University Hospital, Tokyo, Japan.,Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan
| | - K Ogata
- Department of Nursing, Showa University Hospital, Tokyo, Japan
| | - K Maki
- Department of Nursing, Showa University Hospital, Tokyo, Japan
| | - H Sonou
- Department of Nursing, Showa University Hospital, Tokyo, Japan
| | - K Shiga
- Department of Nursing, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - E Otsuka
- Department of Nursing, Showa University Hospital, Tokyo, Japan
| | - M Hiruta
- Department of Nursing, Showa University Hospital, Tokyo, Japan
| | - Y Hirasawa
- Department of Medical Oncology, Showa University, Tokyo, Japan
| | - M Hosonuma
- Department of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - M Murayama
- Department of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - Y Narikawa
- Department of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - H Toyoda
- Department of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - T Tsurui
- Department of Medical Oncology, Showa University, Tokyo, Japan
| | - A Kuramasu
- Department of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| | - M Kin
- Department of Pharmacy, Showa University Hospital, Tokyo, Japan
| | - Y Kubota
- Department of Medical Oncology, Showa University, Tokyo, Japan
| | - T Sambe
- Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa-ku, Japan
| | - A Horiike
- Department of Medical Oncology, Showa University, Tokyo, Japan
| | - H Ishida
- Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | - K Shimada
- Division of Medical Oncology, Internal Medicine Center, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - M Umeda
- Family Hospice Co., Ltd., Tokyo, Japan
| | - T Tsunoda
- Department of Medical Oncology, Showa University, Tokyo, Japan
| | - K Yoshimura
- Department of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
| |
Collapse
|
10
|
Miwa K, Ahn JK, Akazawa Y, Aramaki T, Ashikaga S, Callier S, Chiga N, Choi SW, Ekawa H, Evtoukhovitch P, Fujioka N, Fujita M, Gogami T, Harada T, Hasegawa S, Hayakawa SH, Honda R, Hoshino S, Hosomi K, Ichikawa M, Ichikawa Y, Ieiri M, Ikeda M, Imai K, Ishikawa Y, Ishimoto S, Jung WS, Kajikawa S, Kanauchi H, Kanda H, Kitaoka T, Kang BM, Kawai H, Kim SH, Kobayashi K, Koike T, Matsuda K, Matsumoto Y, Nagao S, Nagatomi R, Nakada Y, Nakagawa M, Nakamura I, Nanamura T, Naruki M, Ozawa S, Raux L, Rogers TG, Sakaguchi A, Sakao T, Sako H, Sato S, Shiozaki T, Shirotori K, Suzuki KN, Suzuki S, Tabata M, Taille CDL, Takahashi H, Takahashi T, Takahashi TN, Tamura H, Tanaka M, Tanida K, Tsamalaidze Z, Ukai M, Umetsu H, Wada S, Yamamoto TO, Yoshida J, Yoshimura K. Precise Measurement of Differential Cross Sections of the Σ^{-}p→Λn Reaction in Momentum Range 470-650 MeV/c. Phys Rev Lett 2022; 128:072501. [PMID: 35244436 DOI: 10.1103/physrevlett.128.072501] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 01/13/2022] [Accepted: 01/13/2022] [Indexed: 06/14/2023]
Abstract
The differential cross sections of the Σ^{-}p→Λn reaction were measured accurately for the Σ^{-} momentum (p_{Σ}) ranging from 470 to 650 MeV/c at the J-PARC Hadron Experimental Facility. Precise angular information about the Σ^{-}p→Λn reaction was obtained for the first time by detecting approximately 100 reaction events at each angular step of Δcosθ=0.1. The obtained differential cross sections show a slightly forward-peaking structure in the measured momentum regions. The cross sections integrated for -0.7≤cosθ≤1.0 were obtained as 22.5±0.68 [statistical error(stat.)] ±0.65 [systematic error(syst.)] mb and 15.8±0.83(stat)±0.52(syst) mb for 470<p_{Σ}(MeV/c)<550 and 550<p_{Σ}(MeV/c)<650, respectively. These results show a drastic improvement compared with past measurements of the hyperon-proton scattering experiments. They will play essential roles in updating the theoretical models of the baryon-baryon interactions.
Collapse
Affiliation(s)
- K Miwa
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Korea
| | - Y Akazawa
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - T Aramaki
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - S Ashikaga
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - S Callier
- OMEGA Ecole Polytechnique-CNRS/IN2P3, 3 rue Michel-Ange, 75794 Paris 16, France
| | - N Chiga
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - S W Choi
- Department of Physics, Korea University, Seoul 02841, Korea
| | - H Ekawa
- High Energy Nuclear Physics Laboratory, RIKEN, Wako 351-0198, Japan
| | - P Evtoukhovitch
- Joint Institute for Nuclear Research (JINR), Dubna, Moscow Region 141980, Russia
| | - N Fujioka
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - M Fujita
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - T Gogami
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Harada
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - S Hasegawa
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - S H Hayakawa
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - R Honda
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - S Hoshino
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - K Hosomi
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - M Ichikawa
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
- Meson Science Laboratory, Cluster for Pioneering Research, RIKEN, Wako 351-0198, Japan
| | - Y Ichikawa
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - M Ieiri
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - M Ikeda
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - K Imai
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - Y Ishikawa
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - S Ishimoto
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - W S Jung
- Department of Physics, Korea University, Seoul 02841, Korea
| | - S Kajikawa
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - H Kanauchi
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - H Kanda
- Research Center for Nuclear Physics (RCNP), Osaka University, Ibaraki 567-0047, Japan
| | - T Kitaoka
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - B M Kang
- Department of Physics, Korea University, Seoul 02841, Korea
| | - H Kawai
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - S H Kim
- Department of Physics, Korea University, Seoul 02841, Korea
| | - K Kobayashi
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - T Koike
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - K Matsuda
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - Y Matsumoto
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - S Nagao
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - R Nagatomi
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - Y Nakada
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - M Nakagawa
- High Energy Nuclear Physics Laboratory, RIKEN, Wako 351-0198, Japan
| | - I Nakamura
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - T Nanamura
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - M Naruki
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - S Ozawa
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - L Raux
- OMEGA Ecole Polytechnique-CNRS/IN2P3, 3 rue Michel-Ange, 75794 Paris 16, France
| | - T G Rogers
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - A Sakaguchi
- Department of Physics, Osaka University, Toyonaka 560-0043, Japan
| | - T Sakao
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - H Sako
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - S Sato
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - T Shiozaki
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - K Shirotori
- Research Center for Nuclear Physics (RCNP), Osaka University, Ibaraki 567-0047, Japan
| | - K N Suzuki
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - S Suzuki
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - M Tabata
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - C D L Taille
- OMEGA Ecole Polytechnique-CNRS/IN2P3, 3 rue Michel-Ange, 75794 Paris 16, France
| | - H Takahashi
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - T Takahashi
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - T N Takahashi
- Nishina Center for Accelerator-based Science, RIKEN, Wako 351-0198, Japan
| | - H Tamura
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - M Tanaka
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - K Tanida
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - Z Tsamalaidze
- Joint Institute for Nuclear Research (JINR), Dubna, Moscow Region 141980, Russia
- Georgian Technical University (GTU), Tbilisi 0175, Georgia
| | - M Ukai
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
- Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan
| | - H Umetsu
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - S Wada
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - T O Yamamoto
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - J Yoshida
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - K Yoshimura
- Department of Physics, Okayama University, Okayama 700-8530, Japan
| |
Collapse
|
11
|
Fujita K, Matsushita M, Motooka D, Hatano K, Nishimoto M, Banno E, Hata J, Tsujimura A, Nakamura S, Minami T, Nozawa M, Yoshimura K, Obara W, Uemura H, Nonomura N. Firmicutes in gut microbiota correlate with blood testosterone levels in elderly men. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00479-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Yoneda T, Tanaka T, Bando K, Choi B, Chang R, Fujiwara Y, Gupta P, Ham D, Karasawa H, Kuwae S, Lee S, Moriya Y, Takakura K, Tsurumaki Y, Watanabe T, Yoshimura K, Nomura M. Nonclinical and quality assessment of cell therapy products: Report on the 4th Asia Partnership Conference of Regenerative Medicine, April 15, 2021. Cytotherapy 2022; 24:892-904. [DOI: 10.1016/j.jcyt.2022.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 01/17/2022] [Accepted: 01/21/2022] [Indexed: 11/03/2022]
|
13
|
Negoro H, Fukunaga A, Setoh K, Kawaguchi T, Funada S, Yoshino T, Yoshimura K, Nishiyama H, Tabara Y, Matsuda F, Ogawa O. Relationship between nocturia and sleep problem in cross-sectional and longitudinal analysis: The Nagahama study. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00918-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Miwa K, Nanamura T, Sakao T, Ahn JK, Akazawa Y, Aramaki T, Ashikaga S, Callier S, Chiga N, Chiga N, Choi SW, Ekawa H, Evtoukhovitch P, Fujioka N, Fujita M, Gogami T, Harada T, Hasegawa S, Hayakawa SH, Honda R, Hoshino S, Hosomi K, Ichikawa M, Ichikawa Y, Ieiri M, Ikedai M, Imai K, Ishikawa Y, Ishimoto S, Jung WS, Kajikawa S, Kanauchi H, Kanda H, Kitaoka T, Kang BM, Kawai H, Kim SH, Kobayashi K, Koike T, Matsuda K, Matsumoto Y, Nagao S, Nagatomi R, Nakada Y, Nakagawa M, Nakamura I, Naruki M, Ozawa S, Raux L, Rogers TG, Sakaguchi A, Sako H, Sato S, Shiozaki T, Shirotori K, Suzuki KN, Suzuki S, Tabata M, Taille CDL, Takahashi H, Takahashi T, Takahashi TN, Tamura H, Tanaka M, Tanida K, Tsamalaidze Z, Ukai M, Umetsu H, Wada S, Yamamoto TO, Yoshida J, Yoshimura K. Recent progress and future prospects of hyperon nucleon scattering experiment. EPJ Web Conf 2022. [DOI: 10.1051/epjconf/202227104001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
A new hyperon-proton scattering experiment, dubbed J-PARC E40, was performed to measure differential cross sections of the Σ+p, Σ−p elastic scatterings and the Σ−p → Λn scattering by identifying a lot of Σ particles in the momentum ranging from 0.4 to 0.8 GeV/c produced by the π±p → K+Σ± reactions. We successfully measured the differential cross sections of these three channels with a drastically improved accuracy with a fine angular step. These new data will become important experimental constraints to improve the theories of the two-body baryon-baryon interactions. Following this success, we proposed a new experiment to measure the differential cross sections and spin observables by using a highly polarized Λ beam for providing quantitative information on the ΛN interaction. The results of three Σp channels and future prospects of the Λp scattering experiment are described.
Collapse
|
15
|
Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Yoshimura K, Behrens C, Pataer A, Parra E, Haymaker C, Fujimoto J, Swisher S, Heymach J, Gibbons D, Lee J, Sepesi B, Cascone T, Solis L, Provencio M, Kadara H, Wistuba I. 7P Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
16
|
Ozaki H, Yoshimura K, Asaoka Y, Hayashi S. Antimony from brake dust to the combined sewer collection system via road effluent under rainy conditions. Environ Monit Assess 2021; 193:369. [PMID: 34052915 DOI: 10.1007/s10661-021-09152-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Accepted: 05/20/2021] [Indexed: 06/12/2023]
Abstract
Abrasion of the brake lining of automobiles is one of the main antimony (Sb) sources on the road. Therefore, the road effluent possibly supplies Sb to the combined sewer collection system. However, Sb in road-sewer systems has attracted little concern, although heavy metals such as copper (Cu), zinc (Zn), cadmium (Cd), and lead (Pb) in sewer water have been studied by many previous authors. We investigated the effect of road effluent on Sb in the combined sewer water by collecting road effluent, road dust, and sewer water under rainy and dry weather conditions. Sb in road effluent showed a significantly higher concentration than the other types of samples, and the Sb concentration in sewer during wet weather was significantly higher than that during dry weather. Furthermore, the Sb concentration in sewer water decreased with time during a wash-off event. Clear positive relationships between Sb and Cu and between Sb and Ba in both road effluent and road dust extract indicate the effect of brake abrasion because the brake lining contains Cu, Sb, and Ba in high concentrations. Approximately 42% of Sb load occurred during the wash-off event, while the loads of Cu and Ba were much less. Unlike Cu and Ba, we conclude that Sb in combined sewer water largely depends on road effluent in wet weather due to the wash-off of road dust, which is probably associated with brake lining abrasion.
Collapse
Affiliation(s)
- H Ozaki
- Fukushima Regional Collaborative Research Center, National Institute for Environmental Studies, Japan, 10-2, Fukasaku, Miharu, Tamura, Fukushima, 963-7700, Japan.
| | - K Yoshimura
- Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 45-169, Kaihama-Sukakeba, Haramachi, Minamisoma, Fukushima, 975-0036, Japan
| | - Y Asaoka
- Department of Civil Engineering, College of Engineering, Nihon University, 1, Nakagawara, Tokusada, Tamura, Koriyama, Fukushima, 963-8642, Japan
| | - S Hayashi
- Fukushima Regional Collaborative Research Center, National Institute for Environmental Studies, Japan, 10-2, Fukasaku, Miharu, Tamura, Fukushima, 963-7700, Japan
| |
Collapse
|
17
|
Yatomi T, Uchida T, Takeuchi H, Kuramochi S, Yoshimura K, Mimura M, Uchida H. Prescription patterns of psychotropics in patients receiving synthetic glucocorticoids. Acta Psychiatr Scand 2020; 142:242-248. [PMID: 32677065 DOI: 10.1111/acps.13217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/10/2020] [Indexed: 12/01/2022]
Abstract
OBJECTIVE Synthetic glucocorticoids cause various psychiatric symptoms. Prescription of psychotropic drugs could be considered to be a proxy for manifestation of psychiatric symptoms. The aim of this study was to investigate the prescriptions of psychotropics in outpatients receiving synthetic glucocorticoids. METHODS We used the claims sampling data during January 2015 from the National Database of Health Insurance Claims and Specific Health Checkups of Japan made by the Ministry of Health, Labor, and Welfare in Japan. We compared the prescription rates of psychotropics between outpatients receiving oral synthetic glucocorticoids and age- and sex-matched controls and the prescription rates of psychotropics among the eight dosage groups of synthetic glucocorticoids by chi-squared test, and chlorpromazine/imipramine/diazepam equivalent doses (or daily defined doses) of respective psychotropics among these groups using Welch's t-test. RESULTS Synthetic glucocorticoids were prescribed to 3.1% (n = 18 122) of 581 990 patients. The prescription rates of psychotropics were significantly higher among the synthetic glucocorticoid recipients than among the non-recipients: antipsychotics, 1.8% (n = 321) vs. 1.1% (n = 201) (P = 1.4 × 10-7 ); antidepressants, 4.0% (n = 724) vs. 2.0% (n = 359) (P = 8.7 × 10-30 ); anxiolytics/hypnotics, 16.7% (n = 3029) vs. 10.2% (n = 1841) (P = 2.7 × 10-75 ); and mood stabilizers, 1.3% (n = 238) vs. 0.7% (n = 120) (P = 3.6 × 10-10 ) respectively. There was no significant difference in the prescription rates of any psychotropic drugs, other than anxiolytics/hypnotics, among the eight synthetic glucocorticoid dosage groups. CONCLUSION Prescriptions of oral synthetic glucocorticoids were found to be associated with the use of any of the types of psychotropic drugs, other than anxiolytics/hypnotics, although a causal relationship could not be confirmed due to the retrospective and cross-sectional nature of this study.
Collapse
Affiliation(s)
- T Yatomi
- Department of Neuropsychiatry, Kawasaki Municipal Hospital, Kanagawa, Japan.,Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - T Uchida
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - H Takeuchi
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - S Kuramochi
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.,Department of Neuropsychiatry, Yamanashi Prefectural Kita Hospital, Yamanashi, Japan
| | - K Yoshimura
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.,Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan
| | - M Mimura
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| | - H Uchida
- Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
18
|
Yoshimura K, Watanabe T, Kurikami H. Vertical and horizontal distributions of 137Cs on paved surfaces affected by the Fukushima Dai-ichi Nuclear Power Plant accident. J Environ Radioact 2020; 217:106213. [PMID: 32217245 DOI: 10.1016/j.jenvrad.2020.106213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 02/14/2020] [Accepted: 02/16/2020] [Indexed: 06/10/2023]
Abstract
Vertical and horizontal distributions are fundamental for sampling and in-situ gamma spectrum measurement strategies. The distributions of 137Cs were investigated for paved surfaces affected by the Fukusima Dai-ichi Nuclear Power Plant accident. Additionally, the effects of the distributions on the measurement uncertainties of in-situ spectrometry were evaluated. Relaxation mass depth, representing the depth profile of 137Cs, was estimated to be less than 0.23 g cm-2. Variation in the relaxation mass depth, of 0.1-0.23 g cm-2, led to a minor error (less than 5%) in the spectral analysis of the137Cs inventory (activity per unit area, kBq m-2). The 137Cs inventory, within a 20 × 20 m square of 400 cells each measuring 1 m2, showed an uneven distribution with large variation; coefficient of variation ranged from 54 to 136% of geometric average inventory of 424 kBq m-2. Increasing the grid size decreased 137Cs inventory variation among cells, revealing the relationship between instrument field of view and the spatial uncertainty of the results of in-situ gamma spectrometry.
Collapse
Affiliation(s)
- K Yoshimura
- Japan Atomic Energy Agency, 45-169 Sukakeba, Minamisoma, Fukushima, 975-0036, Japan.
| | - T Watanabe
- Japan Atomic Energy Agency, 10-2 Fukasaku, Miharu-machi, Fukushima, 963-7707, Japan
| | - H Kurikami
- Japan Atomic Energy Agency, 10-2 Fukasaku, Miharu-machi, Fukushima, 963-7707, Japan
| |
Collapse
|
19
|
Iwano T, Yoshimura K, Inoue S, Odate T, Ogata K, Funatsu S, Tanihata H, Kondo T, Ichikawa D, Takeda S. Breast cancer diagnosis based on lipid profiling by probe electrospray ionization mass spectrometry. Br J Surg 2020; 107:632-635. [PMID: 32246473 PMCID: PMC7216899 DOI: 10.1002/bjs.11613] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Accepted: 03/08/2020] [Indexed: 12/14/2022]
Affiliation(s)
- T Iwano
- Department of Anatomy and Cell Biology, Faculty of Medicine, Yamanashi, Japan
| | - K Yoshimura
- Department of Anatomy and Cell Biology, Faculty of Medicine, Yamanashi, Japan
| | - S Inoue
- Department of Digestive , Breast and Endocrine Surgery, Yamanashi, Japan
| | - T Odate
- Department of Pathology, University of Yamanashi, Chu, Yamanashi, Japan
| | - K Ogata
- Shimadzu Corporation, Nakagyo, Kyoto, Japan
| | - S Funatsu
- Shimadzu Corporation, Nakagyo, Kyoto, Japan
| | - H Tanihata
- Shimadzu Corporation, Nakagyo, Kyoto, Japan
| | - T Kondo
- Department of Pathology, University of Yamanashi, Chu, Yamanashi, Japan
| | - D Ichikawa
- Department of Digestive , Breast and Endocrine Surgery, Yamanashi, Japan
| | - S Takeda
- Department of Anatomy and Cell Biology, Faculty of Medicine, Yamanashi, Japan
| |
Collapse
|
20
|
Izumida E, Suzawa T, Miyamoto Y, Yamada A, Otsu M, Saito T, Yamaguchi T, Nishimura K, Ohtaka M, Nakanishi M, Yoshimura K, Sasa K, Takimoto R, Uyama R, Shirota T, Maki K, Kamijo R. Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption. J Dent Res 2020; 99:429-436. [PMID: 31986066 DOI: 10.1177/0022034520901731] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood. We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification. Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration. PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R. To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation. When differentiated into osteoblastic-lineage cells, PFE-iPSCs showed no abnormality in mineralization. The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2. Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs. In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts. Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
Collapse
Affiliation(s)
- E Izumida
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
- Department of Orthodontics, School of Dentistry, Showa University, Tokyo, Japan
| | - T Suzawa
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - Y Miyamoto
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - A Yamada
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - M Otsu
- Stem Cell Bank & Division of Stem Cell Processing, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Present address: Department of Transfusion and Cell Transplantation, School of Medicine, Kitasato University, Sagamihara, Japan
| | - T Saito
- Division of Tissue Engineering, Department of Bone and Cartilage Regenerative Medicine, University of Tokyo Hospital, The University of Tokyo, Tokyo, Japan
| | - T Yamaguchi
- Department of Orthodontics, School of Dentistry, Showa University, Tokyo, Japan
| | - K Nishimura
- Laboratory for Gene Regulation, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - M Ohtaka
- TOKIWA-Bio, Inc., Tsukuba, Japan
| | - M Nakanishi
- Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan
| | - K Yoshimura
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - K Sasa
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - R Takimoto
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
- Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Tokyo, Japan
| | - R Uyama
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| | - T Shirota
- Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Tokyo, Japan
| | - K Maki
- Department of Orthodontics, School of Dentistry, Showa University, Tokyo, Japan
| | - R Kamijo
- Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
| |
Collapse
|
21
|
Moriwaki T, Hasegawa N, Yamamoto Y, Yamada T, Kanai M, Kobayashi S, Eguchi H, Seo S, Taketomi A, Yoshimura K, Hatano E, Nagano H, Ioka T. Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Ishida T, Tomii K, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim Y, Yoshimura K, Hirai T. Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Tsunedomi R, Yoshimura K, Kimura Y, Nishiyama M, Matsukuma S, Tokumitsu Y, Tomochika S, Iida M, Suzuki N, Takeda S, Yoshino S, Hazama S, Nagano H. Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Yoshimura K, Inoue Y, Tsuchiya K, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Suzuki Y, Karayama M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Suda T, Sugimura H. P2.03-43 WTAP Activates Oncogenes and Accelerates Tumor Aggressiveness Through Adding m6A RNA Modification in Non-Small-Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Yoshimura K, Fujiwara K, Nakama S. APPLICABILITY OF AUTONOMOUS UNMANNED HELICOPTER SURVEY OF AIR DOSE RATE IN SUBURBAN AREA. Radiat Prot Dosimetry 2019; 184:315-318. [PMID: 31095340 DOI: 10.1093/rpd/ncz116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
An autonomous unmanned helicopter (AUH) survey is a useful tool for monitoring the distribution of ambient dose equivalent rates. However, the AUH survey method was developed for plane permeable fields such as agricultural land, and its applicability to urban areas is unclear. In this study, the applicability was investigated by comparing the results of AUH and ground-based surveys conducted in suburban areas, including residential and agricultural lands. The results of both surveys broadly agreed with each other within a factor of 2 in the range independent of land use, and the factor was the same as that reported for plane permeable fields. These results suggest that AUH surveys are applicable in urban areas. The measurement uncertainty of the AUH survey was largely affected by the patchy and local distribution of ambient dose equivalent rates on the ground and differences in the fields of view, rather than land use.
Collapse
Affiliation(s)
- K Yoshimura
- Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 45-169 Sukakeba, Minamisoma, Fukushima, Japan
| | - K Fujiwara
- Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 45-169 Sukakeba, Minamisoma, Fukushima, Japan
| | - S Nakama
- Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 45-169 Sukakeba, Minamisoma, Fukushima, Japan
| |
Collapse
|
26
|
Hirata K, Hamamoto Y, Tsuchihashi K, Kondoh C, Yamazaki K, Hironaka S, Ando M, Imamura C, Yoshimura K, Muro K. Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Kawashima Y, Yamaguchi O, Kozuki T, Furuya N, Kurimoto F, Okuno T, Yamada T, Komiyama K, Ko R, Nagai Y, Ishikawa N, Harada T, Watanabe K, Seike M, Yoshimura K, Kobayashi K, Kagamu H. Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Kawamura K, Nakasone H, Wada H, Akahoshi Y, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tamaki M, Kusuda M, Kameda K, Sato M, Terasako-Saito K, Tanihara A, Kimura SI, Kako S, Kanda Y. PS1277 EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000563388.12959.de] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
29
|
Matsumoto K, Futamura M, Miyaki T, Iwasa T, Imoto S, Doi M, Tokunaga S, Aogi K, Yoshimura K, Takano T. A phase 2 study evaluating dose dense AC (ddAC) followed by dose dense paclitaxel (ddP) supported by 3.6 mg peg-filgrastim (ddAC-ddP3.6) for patients (pts) with primary breast cancer (PBC) in Japan -WJOG9016B-. Breast 2019. [DOI: 10.1016/s0960-9776(19)30103-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
30
|
Ozaki Y, Kitano S, Matsumoto K, Takahashi M, Mukohara T, Futamura M, Masuda N, Tsurutani J, Yoshimura K, Minami H, Takano T. Abstract OT1-12-02: Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In recent years, anti-PD-1 antibody, an immune checkpoint inhibitor, has been developed for the treatment of various types of cancer, including breast cancer. Synergistic effects of nivolumab, paclitaxel and bevacizumab are expected, based on various preclinical data, when these drugs are administered in combination. A biomarker study is ongoing to evaluate the immune status of patients participating in the NEWBEAT trial, which is a phase II trial of nivolumab + paclitaxel + bevacizumab therapy as first-line treatment for patients with metastatic or recurrent HER2-negative breast cancer. Methods: HER2-negative breast cancer patients from the WJOG9917B (NEWBEAT) trial are enrolled in this biomarker study. To explore new biomarkers for combined treatment of breast cancer with immune-checkpoint inhibitors and anti-vascular endothelial growth factor antibodies, we propose to conduct multicolor immunohistochemistry (IHC) assays for immunomonitoring of the intra-tumor environment, such as the expressions of PD-L1, CD4 and CD8. Blood samples are collected before the start of treatment and at four time-points during the treatment, to determine, using a multicolor flow cytometry panel, the numbers of circulating immunosuppressive cells, such as regulatory T cells, myeloid-derived suppressor cells and tumor-associated macrophages (M2). In the NEWBEAT trial, patients receive nivolumab 240 mg/body on days 1 and 15, paclitaxel 90 mg/m2 on days 1, 8 and 15, and bevacizumab 10 mg/kg on days 1 and 15 every 4 weeks until disease progression. The primary endpoint is the objective response rate, and the key secondary endpoints include progression-free survival, overall survival, and toxicity of the protocol treatment. A total of 51 patients will be enrolled and the enrollment period will be one year. This trial opened to accrual in February 2018. Clinical trial registry number: UMIN000029590
Citation Format: Ozaki Y, Kitano S, Matsumoto K, Takahashi M, Mukohara T, Futamura M, Masuda N, Tsurutani J, Yoshimura K, Minami H, Takano T. Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-12-02.
Collapse
Affiliation(s)
- Y Ozaki
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - S Kitano
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - K Matsumoto
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - M Takahashi
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - T Mukohara
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - M Futamura
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - N Masuda
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - J Tsurutani
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - K Yoshimura
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - H Minami
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| | - T Takano
- Toranomon Hospital, Tokyo, Japan; National Cancer Center, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; National Cancer Center Hospital East, Chiba, Japan; Gifu University, Gifu, Japan; NHO Osaka National Hospital, Osaka, Japan; Kindai University, Osaka, Japan; Kanazawa University Hospital, Kanazawa, Japan; Kobe University School of Medicine, Hyogo, Japan
| |
Collapse
|
31
|
Masuishi T, Suzuki T, Sukawa Y, Imamura C, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Kanai T, Takaishi H. Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Kito Y, Yamada T, Matsumoto T, Yasui H, Murata K, Makiyama A, Hara H, Baba E, Nishio K, Yoshimura K, Hironaka S, Muro K, Yamazaki K. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Ishioka C, Sho M, Takeyama Y, Fujimoto J, Toyoda M, Shimizu J, Goto T, Yoshimura K, Hatano E, Nagano H, Ioka T. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
34
|
Ioka T, Sakai D, Wada H, Eguchi H, Yanagihara K, Satake H, Shimizu J, Kanai M, Hashimoto K, Ajiki T, Nakamura M, Takeda Y, Yoshimura K, Hatano E, Nagano H. The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Yoshimura K, Fujii J, Yutsudo T, Kikuchi R, Soejima T, Shirahata S, Yoshida S. No Direct Effects of Shiga Toxin 1 and 2 on the Aggregation of Human Platelets In Vitro. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615248] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
36
|
Kaneko K, Miyamoto Y, Tsukuura R, Sasa K, Akaike T, Fujii S, Yoshimura K, Nagayama K, Hoshino M, Inoue S, Maki K, Baba K, Chikazu D, Kamijo R. 8-Nitro-cGMP is a promoter of osteoclast differentiation induced by RANKL. Nitric Oxide 2017; 72:46-51. [PMID: 29183803 DOI: 10.1016/j.niox.2017.11.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/07/2017] [Accepted: 11/17/2017] [Indexed: 10/18/2022]
Abstract
Osteoclasts are multinucleated giant cells differentiated from monocyte-macrophage-lineage cells under stimulation of receptor activator of nuclear factor κ-B (RANK) ligand (RANKL) produced by osteoblasts and osteocytes. Although it has been reported that nitric oxide (NO) and reactive oxygen species (ROS) are involved in this process, the mechanism by which these labile molecules promote osteoclast differentiation are not fully understood. In this study, we investigated the formation and function of 8-nitro-cGMP, a downstream molecule of NO and ROS, in the process of osteoclast differentiation in vitro. 8-Nitro-cGMP was detected in mouse bone marrow macrophages and osteoclasts differentiated from macrophages in the presence of RANKL. Inhibition of NO synthase suppressed the formation of 8-nitro-cGMP as well as RANKL-induced osteoclast differentiation from macrophages. On the other hand, RANKL-induced osteoclast differentiation was promoted by addition of 8-nitro-cGMP to the cultures. In addition, 8-nitro-cGMP enhanced the mRNA expression of RANK, the receptor for RANKL. However, 8-bromo-cGMP, a membrane-permeable derivative of cGMP, did not have an effect on either RANKL-induced osteoclast differentiation or expression of the RANK gene. These results suggest that 8-nitro-cGMP is a novel positive regulator of osteoclast differentiation, which might help to explain the roles of NO and ROS in osteoclast differentiation.
Collapse
Affiliation(s)
- K Kaneko
- Department of Biochemistry, Showa University School of Dentistry, Japan; Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Japan
| | - Y Miyamoto
- Department of Biochemistry, Showa University School of Dentistry, Japan.
| | - R Tsukuura
- Department of Biochemistry, Showa University School of Dentistry, Japan; Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Japan
| | - K Sasa
- Department of Biochemistry, Showa University School of Dentistry, Japan
| | - T Akaike
- Department of Environmental Health Sciences and Molecular Toxicology, Tohoku University Graduate School of Medicine, Japan
| | - S Fujii
- Department of Environmental Health Sciences and Molecular Toxicology, Tohoku University Graduate School of Medicine, Japan
| | - K Yoshimura
- Department of Biochemistry, Showa University School of Dentistry, Japan
| | - K Nagayama
- Department of Biochemistry, Showa University School of Dentistry, Japan; Department of Orthodontics, Showa University School of Dentistry, Japan
| | - M Hoshino
- Department of Prosthodontics, Showa University School of Dentistry, Japan
| | - S Inoue
- Department of Prosthodontics, Showa University School of Dentistry, Japan
| | - K Maki
- Department of Orthodontics, Showa University School of Dentistry, Japan
| | - K Baba
- Department of Prosthodontics, Showa University School of Dentistry, Japan
| | - D Chikazu
- Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Japan
| | - R Kamijo
- Department of Biochemistry, Showa University School of Dentistry, Japan
| |
Collapse
|
37
|
Uemura H, Kosaka T, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M. Cabazitaxel plus prednisolone with primary prophylaxis with pegfilgrastim (PEG) in Japanese patients with metastatic castration-resistant prostate cancer: An open label prospective phase 2 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx676.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Nosaki K, Takeuchi S, Takahara S, Kawakami T, Yoh K, Kono Y, Horiike A, Seto T, Goto K, Yoshimura K, Imai Y, Murayama T, Yano S. Safety of alectinib in non-small cell lung cancer patients with RET fusion gene (ALL-RET): Results from the dose-finding portion of a phase 1/2 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Fujimoto D, Yokoyama T, Yoshioka H, Demura Y, Hirano K, Kawai T, Kagami R, Ishida T, Tomii K, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim Y, Yoshimura K, Hirai T. A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Yoshimura K, Saito K, Fujiwara K. Distribution of 137Cs on components in urban area four years after the Fukushima Dai-ichi Nuclear Power Plant accident. J Environ Radioact 2017; 178-179:48-54. [PMID: 28778008 DOI: 10.1016/j.jenvrad.2017.07.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 07/26/2017] [Accepted: 07/27/2017] [Indexed: 06/07/2023]
Abstract
Distribution of 137Cs on components in urban areas such as roofs and roads is crucial for evaluating the behavior of radiocesium and ambient dose rates in the area. This study evaluated relative 137Cs inventories, which are defined as the relative values of 137Cs inventory on each component to that on a nearby permeable plane field, for 11 buildings in the evacuation zone about four years after the Fukushima Dai-ichi Nuclear Power Plant accident. The average relative inventory of paved ground accounted for 0.18 of that on permeable plane fields. Other components showed small average values of less than 0.1, indicating rapid removal of radiocesium from urban areas even without decontamination. The differences in the relative inventories on roads and roofs with those in the case of Europe suggest that human activity and component materials largely affect the reduction of radiocesium in urban area.
Collapse
Affiliation(s)
- K Yoshimura
- Japan Atomic Energy Agency, 10-2 Fukasaku, Miharu-machi, Fukushima 963-7707, Japan.
| | - K Saito
- Japan Atomic Energy Agency, 2-2-2 Uchisaiwai-cho, Chiyoda-ku, Tokyo 100-8577, Japan
| | - K Fujiwara
- Japan Atomic Energy Agency, 10-2 Fukasaku, Miharu-machi, Fukushima 963-7707, Japan
| |
Collapse
|
41
|
Hase T, Takeuchi S, Ando M, Hata A, Kenmotsu H, Fujiwara T, Shimizu S, Nagase K, Yoshimura K, Katakami N, Takahashi T, Hasegawa Y, Yano S. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Yoshimura K, Yano I, Yamamoto T, Kawanishi M, Isomoto Y, Yonezawa A, Kondo T, Takaori-Kondo A, Matsubara K. Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2017; 53:44-51. [DOI: 10.1038/bmt.2017.213] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 07/20/2017] [Accepted: 08/27/2017] [Indexed: 11/09/2022]
|
43
|
Takeda K, Kanki R, Yoshimura K, Nakano S. A case report: Neuronal intranuclear inclusion disease (NIID) with suppressive progression over a long period of time. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Yoshimura K, Kanki R, Takeda K, Morihata H, Yamamoto T, Nakano S. Megalencephalic leukoencephalopathy with subcortical cysts and hypothalamic hypoadrenocorticism: Case reports. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Sho T, Hachisuga T, Koi C, Kurita T, Kagami S, Kawagoe T, Matsuura Y, Yoshimura K, Hisaoka M. 17β-Estradiol induces proliferation of endometrial NK cells (CD56+) in postmenopausal women. Climacteric 2017; 20:571-576. [PMID: 28933961 DOI: 10.1080/13697137.2017.1377173] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVE The aim of this report was to evaluate the impact of hormone replacement therapy (HRT) on lymphocytic infiltration of the endometrium in postmenopausal women. METHOD This study included 58 Japanese patients who had undergone hysterectomy at the University Hospital of Occupational and Environmental Health, Japan. Before surgery, nine patients had received 17β-estradiol (E2), 0.72 mg transdermally for 2-8 weeks (E2 group); 16 patients had received an Estra-1,3,5(10)-triene-3,16α, 17β-triol (E3) vaginal tablet 0.5 mg per month five times (E3 group); and 19 patients had received 17β-estradiol, 0.62 mg, and norethindrone acetate (P), 2.70 mg for 3-16 weeks (E2 + P group). Fourteen patients received no HRT (control group). We examined uterine tissue specimens immunohistochemically for CD45+, CD3+, CD4+, CD8+, CD20+, CD56+, and Ki67 antigen-positive cells. RESULTS The numbers of CD56 + cells were significantly increased in the E2 group compared with all other groups (E2 vs. E3: 7.0 vs. 0.75, p = 0.017; E2 vs. E2 + P: 7.0 vs. 0.58, p = 0.009; E2 vs. CONTROL 7.0 vs. 0.43, p = 0.010). The numbers of CD3+ cells were significantly increased in the E2 group compared with the control group (149.3 vs. 42.6, p = 0.008). CONCLUSION 17β-Estradiol induced the proliferation of endometrial uterine natural killer cells (CD56+) in postmenopausal women.
Collapse
Affiliation(s)
- T Sho
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - T Hachisuga
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - C Koi
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - T Kurita
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - S Kagami
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - T Kawagoe
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - Y Matsuura
- a Department of Obstetrics and Gynecology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| | - K Yoshimura
- b Department of Obstetrics and Gynecology , Wakamatsu Hospital of the University of Occupational and Environmental Health , Kitakyushu , Japan
| | - M Hisaoka
- c Department of Pathology and Oncology , University of Occupational and Environmental Health, School of Medicine , Kitakyushu , Japan
| |
Collapse
|
46
|
Kanoh T, Mizumoto T, Yasuda N, Koya M, Ohno Y, Uchino H, Yoshimura K, Ohkubo Y, Yamaguchi H. Selective IgA Deficiency in Japanese Blood Donors:
Frequency and Statistical Analysis. Vox Sang 2017. [DOI: 10.1159/000461396] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
47
|
Abstract
1. The E3 ubiquitin protein ligase 1 (WWP1) gene, the mutation of which causes muscular dystrophy in chickens, is expressed not only in the pectoral muscle, but also in a number of tissues such as the kidney. Therefore, this study examined some parameters related to kidney function in muscular dystrophic (MD) chickens. 2. Plasma osmolality, Na+ and K+ concentrations, aldosterone levels, and the expression of aquaporin (AQP) 2, AQP3, and α subunits of the amiloride-sensitive epithelial sodium channel (αENaC) were analysed in the kidneys of 5-week-old MD chickens and White Leghorn (WL) chickens under physiological conditions or after one day of water deprivation. 3. Plasma osmolality, Na+ concentrations, and plasma aldosterone levels were significantly higher in MD chickens than in WL chickens. αENaC mRNA expression levels were lower in MD chickens than in WL chickens. AQP2 and AQP3 mRNA expression levels were similar in the two strains of chickens. 4. Plasma osmolality correlated with aldosterone levels and AQP2 and αENaC mRNA levels in WL chickens. In MD chickens, plasma osmolality correlated with AQP2 mRNA levels, but not with plasma aldosterone or αENaC mRNA levels. 5. These results suggest that neither water reabsorption nor the expression of AQP2 and AQP3 is impaired in MD chickens and that a WWP1 gene mutation may or may not directly induce an abnormality in Na+-reabsorption in the kidneys of MD chickens, potentially through αENaC.
Collapse
Affiliation(s)
- N Saito
- a Laboratory of Animal Physiology, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan.,b Avian Bioresource Research Center, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| | - H Hirayama
- a Laboratory of Animal Physiology, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| | - K Yoshimura
- a Laboratory of Animal Physiology, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| | - Y Atsumi
- b Avian Bioresource Research Center, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| | - M Mizutani
- b Avian Bioresource Research Center, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| | - K Kinoshita
- b Avian Bioresource Research Center, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| | - A Fujiwara
- c Laboratory Animal Research Station , Nippon Institute for Biological Science , Hokuto , Japan
| | - T Namikawa
- b Avian Bioresource Research Center, Graduate School of Bioagricultural Sciences , Nagoya University , Nagoya , Japan
| |
Collapse
|
48
|
Masuda T, Okubo S, Hara H, Hiraki T, Kitao S, Miyamoto Y, Okai K, Ozaki R, Sasao N, Seto M, Uetake S, Yamaguchi A, Yoda Y, Yoshimi A, Yoshimura K. Fast x-ray detector system with simultaneous measurement of timing and energy for a single photon. Rev Sci Instrum 2017; 88:063105. [PMID: 28667968 DOI: 10.1063/1.4989405] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We developed a fast X-ray detector system for nuclear resonant scattering (NRS) experiments. Our system employs silicon avalanche photo-diode (Si-APD) as a fast X-ray sensor. The system is able to acquire both timing and energy of a single X-ray photon simultaneously in a high rate condition, 106 counts per second for one Si-APD. The performance of the system was investigated in SPring-8, a synchrotron radiation facility in Japan. Good time resolution of 120 ps (FWHM) was achieved with a slight tail distribution in the time spectrum by a level of 10-9 at 1 ns apart from the peak. Using this system, we successfully observed the NRS from the 26.27-keV level of mercury-201, which has a half-life of 630(50) ps. We also demonstrated the reduction of background events caused by radioactive decays in a radioactive sample by discriminating photon energy.
Collapse
Affiliation(s)
- T Masuda
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - S Okubo
- Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
| | - H Hara
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - T Hiraki
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - S Kitao
- Research Reactor Institute, Kyoto University, Osaka 590-0494, Japan
| | - Y Miyamoto
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - K Okai
- Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
| | - R Ozaki
- Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
| | - N Sasao
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - M Seto
- Research Reactor Institute, Kyoto University, Osaka 590-0494, Japan
| | - S Uetake
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - A Yamaguchi
- Quantum Metrology Laboratory, RIKEN, Saitama 351-0198, Japan
| | - Y Yoda
- Japan Synchrotron Radiation Research Institute, Hyogo 679-5198, Japan
| | - A Yoshimi
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - K Yoshimura
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| |
Collapse
|
49
|
Tashiro K, Feng J, Wu SH, Mashiko T, Kanayama K, Narushima M, Uda H, Miyamoto S, Koshima I, Yoshimura K. Pathological changes of adipose tissue in secondary lymphoedema. Br J Dermatol 2017; 177:158-167. [PMID: 28000916 DOI: 10.1111/bjd.15238] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/06/2016] [Indexed: 02/06/2023]
Abstract
BACKGROUND The pathophysiology of lymphoedema is poorly understood. Current treatment options include compression therapy, resection, liposuction and lymphatic microsurgery, but determining the optimal treatment approach for each patient remains challenging. OBJECTIVES We characterized skin and adipose tissue alterations in the setting of secondary lymphoedema. METHODS Morphological and histopathological evaluations were conducted for 70 specimens collected from 26 female patients with lower-extremity secondary lymphoedema following surgical intervention for gynaecological cancers. Indocyanine green lymphography was performed for each patient to assess lymphoedema severity. RESULTS Macroscopic and ultrasound findings revealed that lymphoedema adipose tissue had larger lobules of adipose tissue, with these lobules surrounded by thick collagen fibres and interstitial lymphatic fluid. In lymphoedema specimens, adipocytes displayed hypertrophic changes and more collagen fibre deposits when examined using electron microscopy, whole-mount staining and immunohistochemistry. The number of capillary lymphatic channels was also found to be increased in the dermis of lymphoedema limbs. Crown-like structures (dead adipocytes surrounded by M1 macrophages) were less frequently seen in lymphoedema samples. Flow cytometry revealed that, among the cellular components of adipose tissue, adipose-derived stem/stromal cells and M2 macrophages were decreased in number in lymphoedema adipose tissue compared with normal controls. CONCLUSIONS These findings suggest that long-term lymphatic volume overload can induce chronic tissue inflammation, progressive fibrosis, impaired homeostasis, altered remodelling of adipose tissue, impaired regenerative capacity and immunological dysfunction. Further elucidation of the pathophysiological mechanisms underlying lymphoedema will lead to more reliable therapeutic strategies.
Collapse
Affiliation(s)
- K Tashiro
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.,Department of Plastic Surgery, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan
| | - J Feng
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.,Department of Plastic Surgery, Southern Medical University Nanfang Hospital, 1838 Guangzhou South Ave., Guangzhou, 510515, China
| | - S-H Wu
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan
| | - T Mashiko
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan
| | - K Kanayama
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan
| | - M Narushima
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan
| | - H Uda
- Department of Plastic Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan
| | - S Miyamoto
- Department of Plastic Surgery, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan
| | - I Koshima
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan
| | - K Yoshimura
- Department of Plastic Surgery, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.,Department of Plastic Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan
| |
Collapse
|
50
|
Sukawa Y, Nosho K, Miura Y, Takano T, Ito M, Yonesaka K, Mori M, Tokunaga S, Kawada J, Okuda H, Sakamoto T, Hirashima Y, Uchino K, Miyata Y, Yoshimura K, Yamazaki K, Hironaka S, Boku N, Hyodo I, Muro K. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|